🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
276

Quick answer

Takeda has 276 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. INFS (Intranasal Fentanyl Spray)

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  2. INV21 Low Dose

    Takeda

    Hand, Foot and Mouth Disease

    phase 1 mab completed

    1 trial

  3. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  4. IXAZOMIB

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. IXAZOMIB

    Takeda

    Advanced Non-hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  6. Icatibant (30 mg)

    Takeda

    Hereditary Angioedema (HAE)

    phase 1 small molecule completed

    1 trial

  7. Ixazomib

    Takeda

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  8. Ixazomib

    Takeda

    Precursor Cell Lymphoblastic Leukemia-lymphoma

    phase 1 small molecule terminated

    1 trial

  9. Ixazomib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  10. Ixazomib

    Takeda

    Light-Chain Amyloidosis

    phase 1 small molecule completed

    1 trial

  11. Ixazomib

    Takeda

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial

  12. Ixazomib

    Takeda

    Glioblastoma

    phase 1 small molecule completed

    1 trial

  13. Ixazomib (NINLARO®) capsules / Matching placebo capsules

    Takeda

    Relapsing Remitting Multiple Sclerosis

    phase 1 small molecule active

    1 trial

  14. Ixazomib 2.5 mg

    Takeda

    Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  15. Ketamine

    Takeda

    Ketamine-Induced Brain Activity Changes

    phase 1 small molecule completed

    1 trial

  16. Ketamine

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  17. LDX + Venlafaxine XR

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  18. Lanadelumab

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  19. Lanadelumab

    Takeda

    COVID-19 Pneumonia

    phase 1 small molecule terminated

    1 trial

  20. Lansoprazole

    Takeda

    Gastroesophageal Reflux Disease

    phase 1 small molecule completed

    2 trials

  21. Lanthanum carbonate Granule Formulation

    Takeda

    End Stage Renal Disease

    phase 1 small molecule completed

    1 trial

  22. Lisdexamfetamine Dimesylate

    Takeda

    Healthy

    phase 1 small molecule terminated

    1 trial

  23. Lisdexamfetamine Dimesylate

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  24. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    Attention-Deficit Hyperactivity Disorder

    phase 1 small molecule completed

    1 trial

  25. Lubiprostone

    Takeda

    Other Constipation

    phase 1 small molecule completed

    1 trial

  26. Lubiprostone

    Takeda

    Chronic Constipation, Methanogenesis

    phase 1 small molecule completed

    1 trial

  27. MEDI1341

    Takeda

    Parkinson's Disease

    phase 1 small molecule completed

    2 trials

  28. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  29. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  30. MLN0264

    Takeda

    Advanced Gastrointestinal Malignancies

    phase 1 small molecule completed

    1 trial

  31. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  32. MLN1202

    Takeda

    Healthy Japanese and Caucasian Male Adults

    phase 1 small molecule terminated

    1 trial

  33. MLN2480

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  34. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  35. MLN3126

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  36. MLN3126

    Takeda

    Safety

    phase 1 small molecule terminated

    1 trial

  37. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  38. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  39. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  40. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  41. MT203 80 mg or matching Placebo

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  42. MVC-101

    Takeda

    Solid Tumour

    phase 1 mab terminated

    1 trial

  43. Maribavir

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  44. Maribavir (400 mg)

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  45. Maribavir Commercial Tablet Formulation

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  46. Mesalamine

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  47. Metronidazole + MMX Mesalazine/mesalamine placebo

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  48. Mezagitamab

    Takeda

    Kidney Disease

    phase 1 small molecule completed

    2 trials

Frequently asked questions

How many pipeline programs does Takeda have?

276 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.